AMENDMENT UNDER 37 C.F.R. § 1.111 Attorney Docket No.: Q90950

Application No.: 10/553,596

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

LISTING OF CLAIMS:

1. (currently amended) A spiro-piperidine compound represented by formula (I):

wherein R¹ represents hydrogen, an aliphatic hydrocarbon group which may have a substituent(s) or a cyclic group which may have a substituent(s); and

ring A represents a tetrahydropyrimidin-2-(1H)-one group which may have a substituent(s), in which 2.5-diketopiperazine having a spiro bond at the 3-position is excluded,

a salt thereof, an N-oxide thereof, or a quaternary ammonium salt thereof or a solvate thereof, or a prodrug thereof, provided that 9-benzyl-1,3-dimethyl-1,3,9-triazospiro[5.5]undecan-

2-one; 1,3-dimethyl-1,3,9-triazaspiro[5.5]undecan-2-one; 9-benzyl-1-methyl-1,3,9-triazospiro[5.5]undecan-2-one; and 1-methyl-1,3,9-triazaspiro[5.5]undecan-2-one are excluded.

- 2. (canceled).
- 3. (canceled).
- (currently amended) The spiro-piperidine compound according to claim 1, wherein the ring A is represented by

wherein R^2 and R^5 each independently represents hydrogen, an aliphatic hydrocarbon group which may have a substituent(s), hydroxyl which may be protected, carboxy which may be protected, carbamoyl which may be protected, or a cyclic group which may have a substituent(s),

Attorney Docket No.: Q90950

AMENDMENT UNDER 37 C.F.R. § 1.111

Application No.: 10/553,596

a salt thereof, an N-oxide thereof, or a quaternary ammonium salt thereof or a solvate thereof, or a prodrug thereof.

- 5. (canceled).
- 6. (canceled).
- 7. (currently amended): The spiro-piperidine compound according to claim 1, wherein R1 is a C1-10 aliphatic hydrocarbon group which may have a substituent(s), a salt thereof, an N-oxide thereof, or a quaternary ammonium salt thereof or a solvate thereof, or a prodrug thereof.
- 8. (currently amended): The spiro-piperidine compound according to claim 1, wherein R1 is a 5- to 10-membered monocyclic or bicyclic cyclic group which may have a substituent(s),a salt thereof, an N-oxide thereof, or a quaternary ammonium salt thereof or a solvate thereof, or a prodrug thereof.
- 9. (currently amended): The spiro-piperidine compound according to claim 1, wherein R1 is alkyl having from 1 to 6 carbon atoms substituted with a 3- to 10-membered monocyclic or bicyclic cyclic group which may have a substituent(s), a salt thereof, an N-oxide thereof, or a quaternary ammonium salt thereof-or a solvate thereof, or a prodrug thereof.
- 10. (withdrawn-currently amended) A pharmaceutical composition which comprises the spiro-piperidine compound according to claim 1, a salt thereof, an N-oxide thereof, or a quaternary ammonium salt thereof-or a solvate thereof, or a prodrug thereof, and a pharmaceutically acceptable carrier or diluent.
 - 11. (canceled).
 - 12. (canceled).
 - 13. (canceled).
 - 14. (canceled).
 - 15. (canceled).
 - 16. (canceled).
 - 17. (canceled).

AMENDMENT UNDER 37 C.F.R. § 1.111 Attorney Docket No.: Q90950

Application No.: 10/553,596

18. (canceled).

19. (withdrawn-currently amended) A method for treating diseases selected from the group consisting of asthma, nepohritis, nephropathy, hepatitis, arthritis, rheumatoid arthritis, rhinitis, conjunctivitis, ulcerative colitis, rejection in organ transplantation, immunosuppression, psoriasis, multiple sclerosis, infection with human immunodeficiency virus, atopic dermatitis, uticaria, allergic bronchopulmonary aspergillosis, allergic eosinophilic gastroenteritis, ischemic reperfusion injury, acute respiratory distress syndrome, shock accompanying bacterial infection, diabetes mellitus, cancer metastasis and arteriosclerosis, which comprises administering to a mammal an effective amount of the spiro-piperidine compound according to claim 1, a salt thereof, an N-oxide thereof, or a quaternary ammonium salt thereof or a solvate thereof, or a prodrug-thereof.

20. (canceled).

21. (previously presented): The spiro-piperidine compound according to claim 1, wherein R² is an aliphatic hydrocarbon group which may have a substituent(s) in which the aliphatic hydrocarbon group is selected from the group consisting of ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, hexyl, heptyl, octyl, C2-8 alkenyl and C2-8 alkynyl.